Pacific Capital Partners’s Standard BioTools LAB Stock Holding History

Pacific Capital Partners’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-475,000	Closed	-$608K	–	56
2025 Q4	$608K	Sell	475,000 -850,000	-64%	-$1.14M	0.65%	31
2025 Q3	$1.72M	Sell	1,325,000 -50,000	-4%	-$65.5K	1.92%	21
2025 Q2	$1.65M	Sell	1,375,000 -200,000	-13%	-$222K	1.55%	22
2025 Q1	$1.7M	Buy	1,575,000 +575,000	+58%	+$807K	1.08%	26
2024 Q4	$1.75M	Buy	1,000,000 +175,000	+21%	+$326K	1.03%	28
2024 Q3	$1.59M	Buy	825,000 +75,000	+10%	+$147K	0.93%	31
2024 Q2	$1.33M	Buy	+750,000	New	+$1.83M	0.88%	35

Other funds holding LAB

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Pacific Capital Partners's LAB Position: Q1 2026 in Review

Pacific Capital Partners sold out of Standard BioTools (LAB) in Q1 2026, closing a stake of 475,000 shares — an estimated $608K sold.

Pacific Capital Partners first reported a position in LAB in Q2 2024 and held it in 7 quarters. The position peaked at $1.75M in Q4 2024. 156 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

Pacific Capital Partners reported no remaining Standard BioTools position as of Q1 2026 after selling out during the quarter.
Pacific Capital Partners sold 475,000 Standard BioTools shares in Q1 2026, an estimated $608K.
Pacific Capital Partners first reported a position in Standard BioTools in Q2 2024 and held it in 7 quarters.
Pacific Capital Partners's Standard BioTools position peaked at $1.75M in Q4 2024.
156 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on Pacific Capital Partners's 13F filing for Q1 2026, filed 9 Apr 2026.